Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 2/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 7/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808400 | 1.00 | PDPK1 (0.51) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL1374742 | 1.00 | PDPK1 (0.51) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL67130 | 0.94 | PDPK1 (0.54) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29605437 | 0.94 | PDPK1 (0.54) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Trifluoroacetic Acid SCHEMBL6509652 | 0.88 | HRH4 (0.48) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL6379588 | 0.87 | PDPK1 (0.58) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL725881 | 0.87 | PDPK1 (0.50) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL30610405 | 0.87 | CDK1 (0.53) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL11222102 | 0.85 | PDPK1 (0.63) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL28299226 | 0.85 | POLA1 (0.53) | PDPK1GDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1914 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| US-8288354-B2 | Natural antisense and non-coding RNA transcripts as drug targets | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-10-16 | — | — | US | claimed |
| JP-3471025-B2 | — | — | 2003-11-25 | — | — | JP | claimed |
| US-20030194738-A1 | Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 | DEAN NICHOLAS M (US) | 2003-10-16 | — | — | US | claimed |
| US-20020039741-A1 | Antitumor agent | DEAN NICHOLAS M (US) | 2002-04-04 | — | — | US | claimed |
| EP-0957926-A4 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS INC (US) | 2002-01-23 | — | — | EP | claimed |
| US-6319906-B1 | FOR THERAPY OF AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, FOR INHIBITING ALLOGRAFT REJECTION | ISIS PHARMACEUTICALS | 2001-11-20 | — | — | US | claimed |
| US-6312900-B1 | FOR MODULATING METASTASIS OF MALIGNANT TUMORS VIA MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | claimed |
| JP-2000507833-A | — | — | 2000-06-27 | — | — | JP | claimed |
| EP-0957926-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| EP-4746853-A1 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637682-B2 | Protein translational control | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2026-05-26 | — | — | US | disclosed |
| US-12618071-B2 | Multimeric oligonucleotides with divided strands | MPEG LA, L.L.C. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-0095089-B1 | IMPROVED HOMOGENEOUS BINDING ASSAY METHOD AND REAGENT SYSTEM, TEST KIT AND TEST DEVICE THEREFOR | MILES LABORATORIES, INC. (US) | 1986-03-05 | — | — | EP | disclosed |
| EP-0142299-A2 | Method of measuring polynucleotide and reagent kit for use therein | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1985-05-22 | — | — | EP | disclosed |
| EP-0095089-A1 | Improved homogeneous binding assay method and reagent system, test kit and test device therefor | MILES LABORATORIES, INC. (US) | 1983-11-30 | — | — | EP | disclosed |
| EP-0027631-B1 | FLAVIN ADENINE DINUCLEOTIDE-LABELED PROTEIN AND POLYPEPTIDE CONJUGATES | MILES LABORATORIES, INC. (US) | 1982-05-05 | — | — | EP | disclosed |
| EP-0027631-A1 | Flavin adenine dinucleotide-labeled protein and polypeptide conjugates | MILES LABORATORIES, INC. (US) | 1981-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637682-B2 | Protein translational control | RNGTT, RNMT, METTL16 | PDPK1 3626/4885GDA 3651/4885PI4KA 3603/4885 |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | DACH1, TNNT2, CDH1 | PDPK1 2204/4885GDA 3902/4885PI4KA 4221/4885 |
| US-12618071-B2 | Multimeric oligonucleotides with divided strands | DCLRE1B, MICA, LIG1 | PDPK1 3398/4885GDA 833/4885PI4KA 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.